Papillary Thyroid Cancer - Pipeline Insight, 2024

This “Papillary Thyroid Cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Papillary Thyroid Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Papillary Thyroid Cancer Understanding

Papillary Thyroid Cancer: Overview

Papillary thyroid carcinoma (PTC) is an epithelial malignancy showing evidence of follicular cell differentiation and a set of distinctive nuclear features. It is the most frequent thyroid neoplasm and carries the best overall prognosis. The tumor usually appears as an irregular solid mass but in rare cases, it may have cystic features. One key feature of PTC is its ability to invade adjacent structures like lymphatics. About 10% of patients may present with metastatic disease at initial presentation. The overall prognosis is good for patients less than 45 years of age. Despite its well-differentiated characteristics, papillary carcinoma may be overtly or minimally invasive. In fact, these tumors may spread easily to other organs. Papillary tumors have a propensity to invade lymphatics but are less likely to invade blood vessels. PTC has several histologic variants, which show different patterns of behavior. For example, tall cell PTC (TPPTC) is an uncommon but relatively aggressive variant that is more likely to demonstrate invasion, metastasis, and recurrence. In contrast, the encapsulated follicular variant of PTC (eFVPTC) without capsular or vascular invasion poses so little risk that the American Thyroid Association has recommended that it no longer be considered a carcinoma, and instead be reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).

Papillary Thyroid Cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Papillary Thyroid Cancer pipeline landscape is provided which includes the disease overview and Papillary Thyroid Cancer treatment guidelines. The assessment part of the report embraces, in depth Papillary Thyroid Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Papillary Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Papillary Thyroid Cancer.
• In the coming years, the Papillary Thyroid Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Papillary Thyroid Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Papillary Thyroid Cancer treatment market. Several potential therapies for Papillary Thyroid Cancer are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Papillary Thyroid Cancer market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Papillary Thyroid Cancer) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Papillary Thyroid Cancer Emerging Drugs Chapters

This segment of the Papillary Thyroid Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Papillary Thyroid Cancer Emerging Drugs

CM-24 : Purple BiotechCM24 is a first-in-class clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with significant potential to treat multiple cancers. CEACAM1 is associated with angiogenesis, and is an inter-cellular adhesion regulator of Fas-mediated apoptosis via interaction with ß-catenin that enhances natural killer cell cytotoxicity against tumor cells. High CEACAM1 expression is known to be associated with poor disease prognosis in a number of tumor types. CEACAM1- CEACAM1 and CEACAM1-CEACAM5 immune checkpoint pathways prevent the death of tumor cells through the inhibition of the immune activity of TILs, lowering phosphorylation of immuno-receptors, and reducing SHP1/2 phosphorylation level in T and NK cells. CM24 (Humanized IgG4 mAb) binds specifically to the extracellular domain of CEACAM1 with nano-molar affinity. Blocking CEACAM1- CEACAM1 and CEACAM1-CEACAM5 interactions with CM24 is associated with anti-angiogenic, immune access, and checkpoint release mechanisms and enables cytotoxic activity of lymphocytes and the killing of tumor cells by T and NK cells. Currently, it is in Phase I/II stage of clinical trial evaluation to treat Papillary Thyroid Cancer.

Vemurafenib: RocheVemurafenib is an orally available inhibitor of mutated BRAF-serine-threonine kinase. Vemurafenif is a small molecule that interacts as a competitive inhibitor of the mutated species of BRAF. It is especially potent against the BRAF V600E mutation. Vemurafenib blocks downstream processes to inhibit tumour growth and eventually trigger apoptosis. Vemurafenib does not have antitumour effects against melanoma cell lines with the wild-type BRAF mutation. Currently, it is in Phase II stage of clinical trial evaluation to treat Papillary Thyroid Cancer.

Papillary Thyroid Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Papillary Thyroid Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Papillary Thyroid Cancer

There are approx. 5+ key companies which are developing the therapies for Papillary Thyroid Cancer. The companies which have their Papillary Thyroid Cancer drug candidates in the most advanced stage, i.e. phase II include, Roche.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Papillary Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Papillary Thyroid Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Papillary Thyroid Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Papillary Thyroid Cancer drugs.

Papillary Thyroid Cancer Report Insights

• Papillary Thyroid Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Papillary Thyroid Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Papillary Thyroid Cancer drugs?
• How many Papillary Thyroid Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Papillary Thyroid Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Papillary Thyroid Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Papillary Thyroid Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Hoffmann-La Roche
• Bristol-Myers Squibb
• Purple Biotech
• Helsinn Healthcare SA

Key Products

• Vemurafenib
• CM-24
• Entrectinib
• Alectinib
• TAS0953/HM06

This product will be delivered within 2 business days.